UBS Group
JSPRW icon

UBS Group’s Japer Therapeutics Warrants JSPRW Stock Holding History

UBS Group’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,304
Closed -$133 – 10559
2025
Q1 		$133 Sell
1,304
-1,268
-49% -$200 ﹤0.01% 9927
2024
Q4 		$437 Buy
+2,572
New +$541 ﹤0.01% 9472
2023
Q4 		– Sell
-37
Closed -$2 – 9603
2023
Q3 		$2 Buy
+37
New +$3 ﹤0.01% 9348
2022
Q4 		– Sell
-19,296
Closed -$1K – 10940
2022
Q3 		$1K Buy
19,296
+15,834
+457% +$1.38K ﹤0.01% 9975
2022
Q2 		$0 Sell
3,462
-300
-8% -$58 ﹤0.01% 10632
2022
Q1 		$1K Sell
3,762
-1,000
-21% -$558 ﹤0.01% 9882
2021
Q4 		$7K Buy
+4,762
New +$6.63K ﹤0.01% 9153
2021
Q1 		– Sell
-11
Closed – – 9248
2020
Q4 		$0 Sell
11
-284
-96% -$356 ﹤0.01% 8567
2020
Q3 		$0 Buy
+295
New +$298 ﹤0.01% 8218

Other funds holding JSPRW

Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's JSPRW Position: Q2 2025 in Review

UBS Group sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2025, closing a stake of 1,304 shares — an estimated $133 sold.

UBS Group first reported a position in JSPRW in Q3 2020 and held it in 9 quarters. The position peaked at $7K in Q4 2021. 6 funds tracked by Wall St. Rank hold JSPRW as of Q2 2025.

  • UBS Group reported no remaining Japer Therapeutics Warrants position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 1,304 Japer Therapeutics Warrants shares in Q2 2025, an estimated $133.
  • UBS Group first reported a position in Japer Therapeutics Warrants in Q3 2020 and held it in 9 quarters.
  • UBS Group's Japer Therapeutics Warrants position peaked at $7K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.